Cristina Flores

Prof. Dr. Cristina Flores

Centro de referência em Crohn e colite, Porto Alegre, Rio Grande do Sul, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
UCUniversidade Estadual de Campinas
Universidade Estadual de Campinas
MIMarcello Imbrizi
Marcello Imbrizi
JBJúlio Baima
Júlio Baima
MAMatheus Freitas Cardoso de Azevedo
Matheus Freitas Cardoso de Azevedo
UPUniversidade Estadual de São Paulo
Universidade Estadual de São Paulo
CCCláudio Saddy Rodrigues Coy
Cláudio Saddy Rodrigues Coy
Inflammatory bowel disease (IBD) is an immune-mediated disorder that includes Crohn’s disease (CD) and ulcerative colitis. CD is characterized by a transmural intestinal involvement from the mouth to the anus with recurrent and remitting symptoms that can lead to progressive bowel damage and disability over time.

1 September 2019 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
RPRamir Luan Perin
Ramir Luan Perin
ADAderson Omar Mourão Cintra Damião
Aderson Omar Mourão Cintra Damião
CFCristina Flores
Cristina Flores
JLJuliano Coelho Ludvig
Juliano Coelho Ludvig
DMDaniela Oliveira Magro
Daniela Oliveira Magro
PKPaulo Kotze
Paulo Kotze
BACKGROUND: There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America. OBJECTIVE: To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients. METHODS: Retrospective observational multicentric study of patients with Crohn’s disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw index for CD and Mayo score for UC), mucosal healing, need for surgery and adverse events were evaluated. RESULTS: A total of 90 patients were included (52 with CD and 38 with UC), the majority with previous exposure to anti-TNF agents (88.46% in CD and 76.31% in UC). In CD (as observed analysis) remission rates at weeks 12, 26 and 52 were 42.89% (21/49), 61.9% (26/42) and 46.15% (12/26), respectively. In UC, remission rates at weeks 12, 26 and 52 were 28.94% (11/38), 36.66% (11/30) and 41.17% (7/17). Mucosal healing rates were 36.11% in CD and 43.4% in UC. During the study period, 7/52 CD patients underwent major abdominal surgery and 4/38 UC patients needed colectomy. CONCLUSION: Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.

5 June 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
CFCristina Flores
Cristina Flores
CFCarlos Fernando Francesconi
Carlos Fernando Francesconi
LMLuíse Meurer
Luíse Meurer
The histopathological discrimination of Crohn’s disease [CD] and ulcerative colitis [UC] can be challenging. The aim of this study was to evaluate if quantification of CD30+ lymphocytes and eosinophils in histopathological material improves the accuracy of diagnosis of inflammatory bowel disease. A total of 156 patients were diagnosed with IBD by a gastroenterologist and corroborated by 5 years of follow-up. Patients were treatment naïve at the time of biopsy. Samples were taken from diseased areas of the colon and examined by a gastrointestinal pathologist. The median number of eosinophils in biopsies from affected segments was 42/high power field [hpf] [25.5–63.5] in CD and 98/hpf [67–123] in UC [p < 0.001]. Biopsies containing ≥ 70 eosinophils/hpf field had a sensitivity of 78.3% and a specificity of 71% for the diagnosis of UC ({area under the receiver operating characteristic (ROC) curve 0.767 (95% confidence interval [CI] 0.696–0.838)}. There was a median of three CD30+ cells/hpf [range 2–6] in diseased CD biopsies and 33 cells/hpf [24–52] in diseased UC biopsies [p < 0.001]. The cut-off determined by the ROC curve was 15 (sensitivity 97.4%, specificity 97.4%, positive likelihood ratio (PLR) 17.1, Negative likelihood ratio (NLR) 0.03, area under the curve [AUC]: 0.978; 95% CI 0.95310.999). Routine histopathological assessment with quantification of CD30+ cells is highly accurate at discriminating CD and UC. All the measured parameters are easy to perform, low-cost, and available in most pathological laboratories.

24 March 2023 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
JBJúlio Baima
Júlio Baima
FBFaculdade de Medicina de Botucatu
Faculdade de Medicina de Botucatu
MIMarcello Imbrizi
Marcello Imbrizi
AAAdriana Ribas Andrade
Adriana Ribas Andrade
LCLiliane Andrade Chebli
Liliane Andrade Chebli
AUAposentado da Unifesp
Aposentado da Unifesp
Background: Inflammatory bowel diseases are immune-mediated disorders that include Crohn’s disease (CD) and ulcerative colitis (UC). UC is a progressive disease that affects the colorectal mucosa causing debilitating symptoms leading to high morbidity and work disability. As a consequence of chronic colonic inflammation, UC is also associated with an increased risk of colorectal cancer. Objective: This consensus aims to provide guidance on the most effective medical management of adult patients with UC. Methods: A consensus statement was developed by stakeholders representing Brazilian gastroenterologists and colorectal surgeons (Brazilian Organization for Crohn’s Disease and Colitis [GEDIIB]). A systematic review including the most recent evidence was conducted to support the recommendations and statements. All recommendations/statements were endorsed using a modified Delphi Panel by the stakeholders/experts in inflammatory bowel disease with at least 80% or greater consensus. Results and conclusion: The medical recommendations (pharmacological and non-pharmacological) were mapped according to the stage of treatment and severity of the disease onto three domains: management and treatment (drug and surgical interventions), criteria for evaluating the effectiveness of medical treatment, and follow-up/patient monitoring after initial treatment. The consensus targeted general practitioners, gastroenterologists and surgeons who manage patients with UC, and supports decision-making processes by health insurance companies, regulatory agencies, health institutional leaders, and administrators.

19 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
KGKaroline Soares Garcia
Karoline Soares Garcia
MAMatheus Freitas Cardoso de Azevedo
Matheus Freitas Cardoso de Azevedo
ACAlexandre de Sousa Carlos
Alexandre de Sousa Carlos
LBLuisa Leite Barros
Luisa Leite Barros
JOJane Oba
Jane Oba
ADAderson Omar Mourão Cintra Damião
Aderson Omar Mourão Cintra Damião
Therapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels during induction, at week six. A total of 111 IBD patients were prospectively enrolled, excluding those previously exposed to the drug. ITL ≥ 10 μg/mL was considered optimal. Patients with suboptimal ITL ( 200 ng/mL discontinued IFX. In our study, proactive TDM was associated with persistence in the IFX rate at six months of 82.9%. At that time, rates of clinical, biological, and endoscopic remission in patients under IFX treatment were 80.2%, 73.9%, and 48.1%, respectively. Applying a simplified TDM-guided algorithm during induction seems feasible and can help improve patients’ outcomes in clinical practice.

21 June 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LSLigia Yukie Sassaki
Ligia Yukie Sassaki
SMSender J Miszputen
Sender J Miszputen
RJRoberto Luiz Kaiser Junior
Roberto Luiz Kaiser Junior
WCWilson R Catapani
Wilson R Catapani
MBMauro Bafutto
Mauro Bafutto
GSGenoile Santana
Genoile Santana
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil